Source comparison
Sermorelin vs Ipamorelin: Growth Hormone Pathways Compared
Mechanism Binds GHRH receptors on pituitary somatotrophs to stimulate GH release Binds ghrelin receptors (GHSR-1a) to trigger GH pulse without appetite stimulation Sermorelin preserves natural pulsatility; ipamorelin produces sharper, shorter GH spikes IGF-1 R
This comparison does not assign a generated winner or score.
- Mechanism
- Binds GHRH receptors on pituitary somatotrophs to stimulate GH release
- Binds ghrelin receptors (GHSR-1a) to trigger GH pulse without appetite stimulation
- Sermorelin preserves natural pulsatility; ipamorelin produces sharper, shorter GH spikes
- IGF-1 Response
- Sustained elevation over 12–16 weeks; mean increase 40–60 ng/mL from baseline
- Comparable IGF-1 elevation but more variable inter-individual response
- Both restore IGF-1 into mid-normal range when dosed appropriately
- Side Effect Profile
- Flushing (10–15%), mild headache, rare hyperglycaemia at high doses
- Better tolerated in most cohorts; lower incidence of flushing and headache
- Ipamorelin may be preferred for women sensitive to GHRH-related vasodilation
- Dosing Frequency
- 5 nights per week, subcutaneous injection before bed
- 5–7 nights per week; can be stacked with CJC-1295 for synergistic effect
- Sermorelin monotherapy is simpler; ipamorelin often used in combination protocols
- Regulatory Status
- Prescription required; compounded under 503B or state pharmacy oversight
- Prescription required; identical regulatory pathway
- Both legally available through licensed prescribers only
- Professional Assessment
- Sermorelin is first-line for postmenopausal GH restoration due to mechanism alignment with natural physiology and lower side effect burden. Ipamorelin is second-line or adjunct when GHRH pathway alone produces suboptimal response.